Sinovant Sciences and Roivant Sciences have together launched a new biopharma company focused on developing and commercialising innovative cell therapies in Asia.
Cytovant Sciences will focus on development programs that have the potential to transform the treatment of diseases that are prevalent in Asian patients.
At the same time, the newly launched company has entered into a multi-program license and collaboration agreement with Medigene, a clinical stage biotechnology company focusing on the development of T cell immunotherapies.
Medigene has granted Cytovant exclusive licenses to develop, manufacture, and commercialise its research-stage T cell immunotherapy targeting NY-ESO-1 as well as a DC vaccine targeting WT-1 and PRAME, in Greater China, South Korea, and Japan.
In addition, Cytovant and Medigene have entered into a strategic collaboration and discovery agreement for T-cell receptor (TCR) immunotherapies for two additional targets.
Medigene will be responsible for the generation and delivery of the TCR constructs using its proprietary TCR discovery and isolation platform.
Following this research collaboration period, Cytovant will assume sole responsibility for the development and commercialization of these TCR therapies in the relevant countries.
The TCRs to be generated by Medigene will be tailored specifically to Asian patients.
As per the agreement, Medigene will receive an overall upfront payment of $10 million as well as potential development, regulatory and commercial milestone payments which in aggregate could total over $1 billion for the four products across multiple indications.